Catalyst Health Economics Consultants

Haematology

1. Economic evaluation of the use of prophylactic clodronate to treat multiple myeloma.

Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S25.

2. The annual cost of blood transfusions in the United Kingdom.

Author: JF Guest, V Munro & RF Cookson.
Source: Clinical & Laboratory Haematology 1998; 20, 111-118.

View Abstract

3. Economic impact of using clodronate in the management of patients with multiple myeloma.

Presented at the 38th Meeting of the British Society for Haematology, Glasgow, April 1998 and at the ISH-EHA Combined Haematology Congress, Amsterdam, July 1998.

4. Cost-effectiveness of amphotericin B plus G-CSF compared to amphotericin B in the treatment of a presumed deep-seated fungal infection in neutropenic patients in the UK.

Author: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: Blood 1998; 92(10) Suppl 1 (part 2 of 2): Abstract no: 3746.

5. Cost-effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

Author: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: PharmacoEconomics 1999; 16(5,2): 543-550

View Abstract

6. Economic impact of using clodronate in the management of patients with multiple myeloma.

Author: NJ Bruce, EV McCloskey, JA Kanis & JF Guest.
Source: British Journal of Haematology 1999; 104: 358-364.

View Abstract

7. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Author: EV McCloskey, JF Guest & JA Kanis.
Source: Drugs 2001; 61 (9): 1253-1274

View Abstract

8. The increasing cost of blood transfusions in the UK.

Presented at the American Society for Hematology Annual Meeting, Philadelphia, December 2002 and published in Blood 2002; 100(11): 289a. Abstract 1109.

View pdf

9. The annual cost of blood transfusions in the UK.

Author: SJ Varney & JF Guest.
Source: Transfusion Medicine 2003; 13: 205-218

View Abstract

10. The annual cost to society of blood transfusions in the UK.

Presented at the 8th Congress of the European Hematology Association, Lyon, June 2003 and published in The Hematology Journal 2003; 4(Suppl 2): 243, Abstract 816.

View pdf

11. Cost-effectiveness of pentostatin compared to cladribine in the management of hairy cell leukaemia in the UK.

Presented at the 49th meeting of the British Society of Haematology, Brighton, April 2009.

12. A literature review on the clinical and economic outcomes attributable to first-line treatment for chronic myeloid leukemia with imatinib mesylate and bone marrow transplantation.

Presented at the 12th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Paris, October 2009.

13. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.

Author: JF Guest, H Smith, E Sladkevicius & G Jackson.
Source: Clinical Therapeutics 2009; 31(2): 2398-2415.

View Abstract

14. Utility values for chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Presented at the 13th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Prague, November 2010.

15. Utility values for chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Author: JF Guest, N Naik, E Sladkevicius, J Coombs, EJ Gray.
Source: Leukemia & Lymphoma 2011; 53(5):928-933.

View Abstract

16. Utility values for specific chronic myelogenous leukaemia (CML) chronic phase health states elicited from the general public in the United Kingdom.

To be presented at the 18th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans, May 2013.


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018